Interview with Le Sun, , AbMax
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
Address: 99Kechuang 14th Street,Building 18,Unit 2,Suite 201B,BDA,Beijing 101111,China
Tel: 86-10-59755729
Web: http://www.antibodychina.com/
AbMax Biotechnology Co., Ltd. was established in 2006 and now is a high-tech enterprise and training base for the national life science and technical personnel. AbMax has the world’s most advanced one-stop technology platform for antibodies and kits researching, which has the monoclonal antibody developed in an average of 46 days with a high success rate of 90%. Moreover, AbMax is also the fastest, best and most competitive service provider of antibody developing in China and one of the world’s best service providers of antibody developing.
In the past six years, AbMax provided services for a number of multinational pharmaceutical companies, the domestic and foreign well-known research units and bio-pharmaceutical enterprises and successfully developed thousands of high quality monoclonal antibodies for the antibody drug, protein, peptide, pathogens, small molecules and other antigens and dozens of kits. AbMax also undertook a dozen government major research projects and established the largest pathogen antibody library for emerging/outbreaking infectious diseases in China.
You spent two decades in the US as an academic, executive, and entrepreneur, and then left to return to China and found AbMax. What’s the story behind how you came…
The meteoric growth of the pharmaceutical industry in China in recent years has seen a host of top Chinese talent return home from studying and working overseas to establish their…
Jin Wang, Partner and Co-leader of the McKinsey China Healthcare Practice, shares the wide-ranging scope of her focus on ‘Big Healthcare’ involving work with healthcare service providers and payers, and pharmaceutical…
China’s healthcare system, which impacts 1.4 billion people, is facing serious capacity issues at all stages of the value chain. Against this backdrop, the country is looking at making wholesale…
Given the undeniably challenging and dynamic China market, most industry stakeholders would agree that the paramount factor behind the success of multinationals’ China affiliates is talent – not only at…
2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From…
Valtero Canepa, general manager for China of Italian family-owned diagnostic imaging specialist Bracco, outlines the importance of China for the firm, the complexities of operating an international joint venture, and…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Li Qing of Illumina China discusses his recent move to the company, the strategic significance of the China market to Illumina global, and the competitive landscape for next generation sequencing…
Japanese ophthalmology specialist Santen first established a China affiliate in 2005 and has grown very successfully in the past 14 years. GM of Santen Pharmaceutical (China) Co., Ltd. (hereafter, Santen…
China’s pharma market is growing at an unprecedented pace and has become a key element of virtually all pharma multinationals’ international strategies. However, with a spate of regulatory reforms being…
Kirsch Pharma is a raw materials provider to the pharmaceutical, nutritional, biotechnology, veterinary and cosmetic industries. The business in China was established in 1997, importing high-quality raw materials from Germany.…
Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an…
See our Cookie Privacy Policy Here